RecruitingNCT05943002

Patient-reported, Health Economic and Psychosocial Outcomes in Friedreich Ataxia


Sponsor

German Center for Neurodegenerative Diseases (DZNE)

Enrollment

200 participants

Start Date

Jun 1, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

The PROFA study is an international, multi-centric observational and validation study to assess the patient-reported, psychosocial and economic outcomes of patients with Friedreich Ataxia (FA). Eligible patients will be recruited from six study centers in Germany, Austria and France. Patients will complete a baseline assessment via face-to-face interviews at the study centers and multiple momentary follow-up assessments via a mobile-health app at home daily to monthly for six months. Study results will gain essential and in-depth insights into the daily life of patients with FA.


Eligibility

Min Age: 12 Years

Inclusion Criteria4

  • FA confirmed by molecular genetic testing
  • Ataxia severity of ≤30 points according to the Scale of the Assessment and Rating of Ataxia (SARA)
  • Access to a smartphone or tablet and able to operate the device
  • Older than 12 years

Exclusion Criteria2

  • Lack of ability to give consent
  • Ataxia severity \>30 according to the Scale of the Assessment and Rating of Ataxia (SARA)

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(6)

Klinik für Neurologie, Medizinische Universität Innsbruck

Innsbruck, Austria

Paris Brain Institute

Paris, France

Department of Neurology, RWTH Aachen University

Aachen, Germany

German Center for Neuro-degenerative Diseases (DZNE)

Bonn, Germany

Friedrich-Baur-Institut an der Neurologischen Klinik und Poliklinik

Münich, Germany

Neurologische Klinik und Hertie-Institut für Klinische Hirnforschung, Universitätsklinik Tübingen

Tübingen, Germany

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05943002


Related Trials